Decellularized Liver Matrix Model for Fibrosis Screening

Resolve Bottlenecks,
Find Innovative Solutions
Generate Solutions

Solution Overview

Problem

Current models for studying liver fibrosis lack relevance and viability, limiting the effectiveness of screening anti-fibrotic agents and understanding disease mechanisms, as they do not accurately replicate real liver tissue conditions.

Innovation Solution

A model system for liver fibrosis is developed, comprising a decellularized liver extracellular matrix combined with mammalian liver cells, including liver progenitor cells, Kupffer cells, and hepatic stellate cells, which can be used in tissue culture dishes, modular devices, or implanted in vivo, allowing for the screening of anti-fibrotic agents by measuring their effect on fibrosis induction or inhibition.

Engineering Contradictions & Design Principles

VSEngineering Contradiction Analysis

1Reliability

If cell culture models with cell lines or viable liver slices are used for studying liver fibrosis, then the research can be conducted in vitro, but the models lack pertinence to real liver tissue and/or viability

Engineering Contradiction:
Improverelevance to real liver tissueVSAvoidmodel system complexity
Core Design Contradiction:
ReliabilityVSDevice complexity

Solution Approach 1:

The invention segments the liver tissue into distinct functional components: decellularized extracellular matrix scaffold and separately cultured liver cell types (hepatocytes, hepatic stellate cells, Kupffer cells). These segmented components are then reassembled into a composite model that replicates native liver architecture and cell-cell interactions, thereby improving physiological relevance while maintaining experimental controllability

Inventive Principle:
Principle #1Segmentation

Solution Approach 2:

The invention creates a composite model system combining decellularized liver extracellular matrix with multiple types of viable liver cells. This composite structure integrates the structural integrity of the matrix scaffold with the functional properties of living cells, achieving both physiological relevance and experimental viability that neither component could provide alone

Inventive Principle:
Principle #40Composite materials

2Stability of the object's composition

If a decellularized liver organoid with vascularized structure is generated, then the structural integrity is improved, but the complexity of the model increases

Engineering Contradiction:
Improvestructural integrityVSAvoidmodel system complexity
Core Design Contradiction:
Stability of the object's compositionVSDevice complexity

Solution Approach 1:

The invention applies preliminary action by first decellularizing intact liver tissue to preserve the native extracellular matrix architecture and vascular structures before seeding liver cells. This pre-prepared scaffold provides immediate structural integrity and physiological cues, eliminating the need to build complex structures from scratch and reducing overall model development complexity

Inventive Principle:
Principle #10Preliminary action

Data Source

PatentEP3414319B1Model system of liver fibrosis and method of making and using the same
Publication Date: 2024.07.24 WAKE FOREST UNIVERSITY HEALTH SCIENCES INC
  • EP3414319B1 patent drawingFigure 1A
  • EP3414319B1 patent drawingFigure 1B
  • EP3414319B1 patent drawingFigure 1C

AI summary

Provided herein is a model system for liver fibrosis, including a liver extracellular matrix, and a combination of mammalian liver cells (e.g., primary liver cells) on the matrix. In some embodiments, the combination of liver cells includes: (a) liver progenitor cells, (b) Kupffer cells, and (c) hepatic stellate cells. Methods of making the model system and methods of use of the model system for screening active agents are also provided.